DJ Epigenomics (ECX-DE): Key catalysts to fuel growth throughout 2019
goetzpartners securities Limited
Epigenomics (ECX-DE): Key catalysts to fuel growth throughout 2019
16-May-2019 / 14:16 GMT/BST
*Free to access research and investor meetings in a post-MiFID2 world.*
*This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.*
*Published to the market and investors on 16th May 2019 @ 7.02am (BST).*
*Epigenomics (ECX-DE): Key catalysts to fuel growth throughout 2019*
*Recommendation: OUTPERFORM*
*Target Price: EUR4.01*
*Current Price: EUR1.90 (CoB on 15th May 2019) *
*KEY TAKEAWAY*
Epigenomics reported Q1/2019 sales of EUR331k (7% YoY), driven largely by a
198% YoY increase in product revenue, which was in part offset by lower
licensing revenue due to the recently announced termination of the
collaboration with Chinese licensing partner BioChain. We expect solid
underlying growth momentum to continue throughout 2019, with back-end loaded
revenue generation in Q3 and Q4 fuelled by a number of commercial as well as
regulatory catalysts that can unlock significant sales potential for Epi
proColon as well as support the commercialisation of HCCBloodTest, the latest
addition to Epigenomic's growing portfolio of liquid biopsy tests, which
allows for blood-based detection of liver cancer. We continue to see the
positive commercial outlook of Epigenomic's liquid biopsy tests due to a
differentiated profile, fast readouts, large target markets and a significant
health-economic impact. We maintain and reiterate both our OUTPERFORM
recommendation and EUR4.01 target price ("TP").
*Q1/2019 financial results*
Epigenomics reported total Q1/2019 revenue of EUR331k, an increase of 7%
compared to Q1/2018. Total revenue was primarily driven by strong product
sales growth (198% YoY), which was in part offset by a decrease in licensing
revenue due to termination of the distribution agreement with Chinese partner
BioChain. Other income attributable to exchange rate gains amounted to EUR499k
(vs. EUR10k in Q1/2018). R&D expenses of EUR1.6m were broadly in line with
last year (2% YoY), while SG&A expenses increased significantly to EUR2.4m
from EUR1.8m (32% YoY) as a result of higher marketing expenses to fuel
commercial development. Epigenomics closed Q1 with an improved net loss
position of EUR-3.0m (-6% YoY) and as of March 31, 2019, cash stood at
EUR12.9m, which should allow the company to fund operations well into 2020E.
*Continued progress on CMR coverage for Epi proColon*
Epigenomics recently announced that the Centers for Medicare & Medicaid
Services ("CMS") has accepted the company's application for a National
Coverage Determination ("NCD") review of Epi proColon, which constitutes one
of two pathways to obtaining CMS coverage. While CMS have not yet initiated
the review process due to a lack of resources available at present, CMS will
issue a proposed decision within six months of starting the process, which
management expect to begin in due course. A positive decision would represent
a major breakthrough for Epigenomics, and we anticipate on-going updates on
timelines and assume share price momentum along with positive news flow.
*Rich news flow expected to catalyse growth throughout 2019*
Having reached a number of critical milestones in 2018, we expect the positive
momentum to continue throughout 2019 and anticipate rich news flow driven by
(1) publication of the results from the microsimulation study in Q2/2018,
paving the way for inclusion into the colorectal cancer screening guidelines,
(2) a potential green light from the CMS for Epi proColon, which would
translate into immediate coverage in the US, (3) progress on the prospective
clinical study for liver cancer detection, and (4) an update on a new
distribution agreement in China. As such, 2019 represents a decisive year for
Epigenomics that, in our view, could lay a solid foundation for sustainable
long-term growth.
*Valuation suggests ample upside*
With the recent CE marking for HCCBloodTest, in our view, the key uncertainty
remains medicare coverage and inclusion into medical guidelines for Epi
proColon. With the new liver product de-risking the commercial outlook,
Epigenomics offers a highly attractive investment opportunity with significant
potential for growth. We maintain and reiterate both our OUTPERFORM
recommendation and TP of EUR4.01.
Kind regards,
Martin Piehlmeier | Analyst
goetzpartners Healthcare Research Team | Research Team
goetzpartners securities Limited
The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.
T +44 (0) 203 859 7725 | martin.piehlmeier@goetzpartners.com /
healthcareresearch@goetzpartners.com
www.goetzpartnerssecurities.com [1]
goetzpartners securities LinkedIn page [2]
Registered in England No. 04684144.
Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.
*goetzpartners securities Limited - Team Members*
Equity Research Analysts - Martin Brunninger, Brigitte de Lima, Chris Redhead,
Martin Piehlmeier and Kieron Banerjee.
Sales / Marketing - Erland Sternby and Danny de Jong.
Corporate Finance - Ulrich Kinzel, Wolf Dornbusch and Youchen Xin.
Corporate Access and IR - Tanya Tracey and Bettina Ellinghorst.
Compliance / Research Production - Paul W. Dunne.
Click here [3] to see our privacy policy.
GPSL has a formal client relationship with Epigenomics AG.
GPSL publishes and distributes "Corporate Issuer Sponsored" Research. Our
Corporate Issuer Sponsored Research and investor meetings (e.g. NDRs, 1 to 1
meetings) are free to access and attend and is not classified as an inducement
in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does
not offer any execution or market making services. This is a marketing
communication as defined by the Financial Conduct Authority ("FCA"). The
information herein is considered to be an acceptable minor non-monetary
benefit as defined under FCA COBS 2.3A19(5).
In accordance with the General Data Protection Regulation ("GDPR [4]") - if
you would like to be removed / unsubscribed from our CRM (also please note
that you are free to contact GPSL at any time in the future to have your
e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com
About GPSL [1]: goetzpartners securities Limited is a member of the
goetzpartners group, and a leading pan European investment bank and research
company. We bring together a wide range of expertise, insights and innovations
to advance the interests of our clients around the world. The fast-changing
environment brings challenges for businesses and investors. Research
innovation, digital transformation and disruptive business ideas reshuffle the
corporate world at a relentless pace. Our sector knowledge and our global
footprint bring together corporate intelligence and a deep understanding of
the industry with a wide network of top decision makers. These collective
insights help our clients to stay at the leading edge of change.
This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.
This communication (including any attachments) from goetzpartners securities
Limited ("GPSL") is confidential and may contain information which is
proprietary, privileged or otherwise legally protected against unauthorised
use or disclosure. If you receive this communication in error or are not the
intended recipient of this communication, please delete and destroy all copies
in your possession, notify the sender that you have received this
communication, and note that any review or dissemination of, or the taking of
any action in reliance on this communication is expressly prohibited. GPSL
shall not be liable for the improper or incomplete transmission of the
information contained in this communication nor for any delay in its receipt
or damage to your system. GPSL does not guarantee that the integrity of this
communication has been maintained nor that this communication is free of
viruses, interceptions or interference and makes no warranties in relation to
these matters. This is not an offer or a solicitation to buy or sell
securities or investment products, or an official confirmation. GPSL record
electronic and phone communications in accordance with FCA and MiFID2
regulations, they will be monitored for regulatory and training purposes. GPSL
[5] is authorised and regulated by the Financial Conduct Authority of the
United Kingdom (Firm Reference Number: 225563).
Click on the following link for the GPSL MiFID2 Investor Guidance Notice [6]
GPSL Equity Research publications are available on the following aggregators
and via news distribution circuits (For Institutional Use Only): AlphaMetry
[7], AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, ResearchFN [8],
Research Tree [9], RNS Reach, Sentieo [10] and Thomson Reuters.
Please copy the below link and paste it into your browser for the full pdf
version of the equity research report:
https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=924fae3f-1ffb-422e-b
297-8d4b6a43d169&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=library
View [11]
*Free to access research and investor meetings in a post-MiFID2 world.*
*This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.*
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
812491 16-May-2019
(MORE TO FOLLOW) Dow Jones Newswires
May 16, 2019 09:16 ET (13:16 GMT)
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=750ca54579c5d5447638f7f35718f4d1&application_id=812491&site_id=vwd&application_name=news 2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=4e235136b3fff70f6e9b300faf1356df&application_id=812491&site_id=vwd&application_name=news 3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e4cf3d45df1d07e4e36e54790266d6f1&application_id=812491&site_id=vwd&application_name=news 4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=105c239b1a4ab584252dd4cb0ab60fcc&application_id=812491&site_id=vwd&application_name=news 5: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ba4d174d6cc17a15461e9920a97cb6e6&application_id=812491&site_id=vwd&application_name=news 6: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3a7dca011f706488817dc0ced9cb1594&application_id=812491&site_id=vwd&application_name=news 7: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=74ec96f086effd6902b227645be3904c&application_id=812491&site_id=vwd&application_name=news 8: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=4ca72a1f25bfe4e057f55b4178d31406&application_id=812491&site_id=vwd&application_name=news 9: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e6502ecec4e43c9ec21d32670b12b227&application_id=812491&site_id=vwd&application_name=news 10: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e3895772493fb088c9401b3187f667a7&application_id=812491&site_id=vwd&application_name=news 11: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=40c5a69cdd7ac3acbe5024c78f43de27&application_id=812491&site_id=vwd&application_name=news
(END) Dow Jones Newswires
May 16, 2019 09:16 ET (13:16 GMT)
© 2019 Dow Jones News
